Cancer-Focused Pharma Invests in Medidata Technology to Automate Clinical Trial Site Reimbursement Process
NEW YORK, N.Y. –
Medidata
, the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that multinational pharmaceutical company
Polaris Pharmaceuticals, Inc.
has selected Medidata Payments to streamline its clinical trial site reimbursement process. “We chose to partner with Medidata because of its innovative technology and ability to integrate and automate site payments with EDC,” said Max Barker, general counsel and VP, finance at Polaris Pharmaceuticals. The life sciences industry spends billions of dollars in global R&D efforts every year, allocating upwards of 40% of clinical trial budgets to sites. Without modern, automated technologies, trial sponsors and their contract research organization (CRO) partners are left struggling with high volumes of invoices and slow, manual and error-prone data entry systems. Recently named a
2016 Scrip Awards finalist
, Medidata Payments is addressing an unmet industry need-offering a single, unified tool that is fit to pay all clinical research sites worldwide and scalable to use across hundreds of studies. By reducing the complexities associated with timely and accurate site reimbursements, Medidata’s end-to-end, EDC-driven solution is enabling companies like Polaris Pharmaceuticals to spend more time on cutting-edge medical advancements and less time sorting through complicated payment terms. Focused on developing novel therapies in the area of oncology, Polaris will leverage the powerful, out-of-the-box integration of Medidata Payments and Medidata Rave (Medidata’s unified electronic data capture, management and reporting tool) to automatically trigger, calculate and disburse investigator payments to its global clinical trial sites. Barker added: “Tracking and managing trial costs are key to our finance team, particularly with multi-site global studies. By connecting Medidata Rave and Payments, we expect to enable our team to focus on analyzing trial costs to drive process improvements instead of spending time requesting and reviewing traditional invoices. This, in turn, will help our sites get paid faster and more accurately for all their hard work.” “At Medidata, we believe that the moment work is completed, sites should be paid accurately and on time, regardless of their location, currency or tax implications,” said April Mulroney, Medidata’s managing director of Payments. “We’re thrilled that Polaris will benefit from our active, EDC-driven payments technology, which will help to streamline and provide real-time visibility into day-to-day payment activities.”
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.